AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8343002 — intervention group
Group type: COMPARATOR
Intervention: Dual-lumen 10 French tunneled cuffed silastic central venous access catheter
Number of subjects: 200
Study 8343002 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-lumen 10 French tunneled cuffed silastic central venous access catheter with a second proximal subcutaneous silver-impregnated cuff
Number of subjects: 200
Study 8343002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both catheter types
Number of subjects: 200
Study 3741095 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep leg veins as femoropopliteal bypass grafts
Number of subjects: 82
Study 29676975 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal/self-etch (SU_SE)
Number of subjects: 63
Study 29676975 — intervention group
Group type: COMPARATOR
Intervention: Prime & Bond Elect/etch-and-rinse (PBE_E&R)
Number of subjects: 63
Study 27901218 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated safety catheter
Number of subjects: 169
Study 27901218 — intervention group
Group type: COMPARATOR
Intervention: Simple needle catheter
Number of subjects: 169
Study 27901218 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gauge catheter
Number of subjects: 169
Study 27901218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid solutions
Number of subjects: 169
Study 27901218 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 169
Study 24809360 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited-undermining lipoabdominoplasty
Number of subjects: 18
Study 24809360 — intervention group
Group type: COMPARATOR
Intervention: Traditional abdominoplasty with wide undermining
Number of subjects: 18
Study 24809360 — intervention group
Group type: COMPARATOR
Intervention: Control group (Traditional abdominoplasty)
Number of subjects: 18
Study 24809360 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (Limited-undermining lipoabdominoplasty)
Number of subjects: 18
Study 22607269 — intervention group
Group type: COMPARATOR
Intervention: Single doses of S1RA (5-500 mg, study 101; 500-800 mg, study 106)
Number of subjects: 175
Study 22607269 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of S1RA (50-400 mg once daily for 8 days, study 102)
Number of subjects: 175
Study 22607269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 20798179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-extremity exercise and walking intervention
Number of subjects: 79
Study 20798179 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular foot care, foot care education, and 8 sessions with a physical therapist)
Number of subjects: 79
Study 18590952 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine administration in MDD/AUD group
Number of subjects: 169
Study 12215958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-arginine hydrochloride salt
Number of subjects: 8
Study 12215958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9641434 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg orally twice per day)
Number of subjects: 20
Study 9641434 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 20
Study 9641434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15378949 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon (alpha-IFN) administered at a dose of 3 x 10(6) U three times per week until disease progression.
Number of subjects: 73
Study 15378949 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group) for patients who obtained a complete or partial response after FLU therapy.
Number of subjects: 73
Study 2530145 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae Hansen CBS 5926 (Perenterol)
Number of subjects: 139
Study 2530145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 1099894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g D-isoascorbic acid
Number of subjects: 210
Study 1099894 — intervention group
Group type: COMPARATOR
Intervention: 1 g L-ascorbic acid
Number of subjects: 210
Study 1099894 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 210
Study 31773143 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin (suspension or tablets, twice daily for 10 days)
Number of subjects: 148
Study 31773143 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (suspension or tablets, 4 times daily for 10 days)
Number of subjects: 148
Study 31773143 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 148
Study 31773143 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 148
Study 31773143 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin and Vancomycin
Number of subjects: 148
Study 29072214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment
Number of subjects: 19
Study 26399399 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture plus as-needed salbutamol aerosol and/or prednisone tablets
Number of subjects: 0
Study 26399399 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture plus as-needed salbutamol aerosol and/or prednisone tablets
Number of subjects: 0
Study 23290835 — intervention group
Group type: EXPERIMENTAL
Intervention: VPM1002 (Mycobacterium bovis BCG ΔureC::hly Hm(R)), administered as one intradermal dose, randomized to three escalating doses.
Number of subjects: 80
Study 23290835 — intervention group
Group type: COMPARATOR
Intervention: BCG (control group), 10 individuals in each group (BCG-naïve and BCG-immune).
Number of subjects: 80
Study 20695794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 40
Study 20695794 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study 18380539 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 92
Study 18380539 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 92
Study 18380539 — intervention group
Group type: COMPARATOR
Intervention: Control group (DM1)
Number of subjects: 92
Study 17096618 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week stress management program
Number of subjects: 0
Study 17096618 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional 'refresher' sessions
Number of subjects: 0
Study 17096618 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 14685663 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 14685663 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 11357021 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic‐assisted colectomy
Number of subjects: 97
Study 11357021 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 97
Study 11357021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surgical techniques
Number of subjects: 97
Study 9149193 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pouch
Number of subjects: 27
Study 9149193 — intervention group
Group type: EXPERIMENTAL
Intervention: Short pouch
Number of subjects: 27
Study 9149193 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 9149193 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 27
Study 7714143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Ig) 500 mg/kg prior to the next embryo transfer
Number of subjects: 29
Study 3443063 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 2.5mg bid for 7 days
Number of subjects: 12
Study 3443063 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5mg bid for 7 days
Number of subjects: 12
Study 3443063 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10mg bid for 1 week
Number of subjects: 12
Study 3443063 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10mg single dose
Number of subjects: 12
Study 3443063 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10mg bid
Number of subjects: 12
Study 3443063 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (various doses)
Number of subjects: 12
Study 3443063 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 12
Study 31248662 — intervention group
Group type: EXPERIMENTAL
Intervention: Veverimer (6 g/day)
Number of subjects: 196
Study 31248662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 29235659 — intervention group
Group type: EXPERIMENTAL
Intervention: Open‐label, protocolized treatment with extended‐release venlafaxine for 12 or more weeks
Number of subjects: 435
Study 25145693 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral methylprednisolone (oMP)
Number of subjects: 49
Study 25145693 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (ivMP)
Number of subjects: 49
Study 24432677 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling at right Waiguan (SJ5) in Group A
Number of subjects: 21
Study 24432677 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling at non-acupoint (10 mm beside Waiguan) in Group B
Number of subjects: 21
Study 24432677 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 21
Study 24432677 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between Group A and Group B
Number of subjects: 21
Study 21452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape seed proanthocyanidin extract (GSPE)
Number of subjects: 100
Study 19015193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (5K(Fent), L3‐L4)
Number of subjects: 8
Study 19015193 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (5K(Plac), L3‐L4)
Number of subjects: 8
Study 17092242 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate (APC) applied in test defects
Number of subjects: 25
Study 17092242 — intervention group
Group type: COMPARATOR
Intervention: Control procedure without APC
Number of subjects: 25
Study 15148011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Library systematic reviews
Number of subjects: 0
Study 15148011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane trials database
Number of subjects: 0
Study 11549975 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fluticasone propionate (176 or 200 mcg daily) for 6‐26 weeks
Number of subjects: 1614
Study 11549975 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fluticasone propionate (100 mcg daily) for 12‐52 weeks
Number of subjects: 1614
Study 11549975 — intervention group
Group type: COMPARATOR
Intervention: Low-dose beclomethasone dipropionate (336 mcg daily)
Number of subjects: 1614
Study 9331520 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT) prophylaxis
Number of subjects: 15
Study 7964957 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa 3 MU three times weekly
Number of subjects: 522
Study 7964957 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alfa 5 MU three times weekly plus DEX
Number of subjects: 522
Study 7964957 — intervention group
Group type: COMPARATOR
Intervention: Higher dose-intensity glucocorticoids
Number of subjects: 522
Study 3655306 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated paracentesis plus i.v. albumin infusion (n = 20)
Number of subjects: 41
Study 3655306 — intervention group
Group type: COMPARATOR
Intervention: Diuretics (n = 21)
Number of subjects: 41
Study 29788137 — intervention group
Group type: EXPERIMENTAL
Intervention: TELE‐IBD EOW (every other week)
Number of subjects: 219
Study 29788137 — intervention group
Group type: EXPERIMENTAL
Intervention: TELE‐IBD W (weekly)
Number of subjects: 219
Study 29788137 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 219
Study 27488380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intermittent pneumatic compression (IPC) and pharmacologic prophylaxis
Number of subjects: 2000
Study 27488380 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic prophylaxis alone
Number of subjects: 2000
Study 25173199 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 100
Study 25173199 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 100
Study 22519127 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone/salmeterol (group A)
Number of subjects: 30
Study 22519127 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide/formoterol (group B)
Number of subjects: 30
Study 20691689 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg CDC
Number of subjects: 36
Study 20691689 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg CDC
Number of subjects: 36
Study 20691689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18500596 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube (LT)
Number of subjects: 50
Study 18500596 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ET)
Number of subjects: 50
Study 16538529 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (Tam) 20 mg per day orally for 5 years
Number of subjects: 541
Study 16538529 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (Tam) plus Fluoxymesterone (Flu) 10 mg orally twice per day for 1 year
Number of subjects: 541
Study 12654164 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated isoflavone supplement (86 mg/d, derived from red clover)
Number of subjects: 25
Study 12654164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10891022 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO‐ORS
Number of subjects: 97
Study 10891022 — intervention group
Group type: COMPARATOR
Intervention: C‐ORS
Number of subjects: 97
Study 8648872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice and advance directives
Number of subjects: 0
Study 1418893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam
Number of subjects: 212
Study 1418893 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 212
Study 6363740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole and trimethoprim
Number of subjects: 120
Study 6363740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31049414 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care at public health facilities including clinical care guides, drugs for COPD, patient education flipcharts, staff training, and mobile phone follow-up.
Number of subjects: 313
Study 31049414 — intervention group
Group type: COMPARATOR
Intervention: Standard care at public health facilities (control group).
Number of subjects: 313
Study 31049414 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of intervention vs control.
Number of subjects: 313
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Female garment workers experiencing IPV
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Worker's ability to mobilize resources in crises
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Savings beyond a threshold
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ownership of jewellery/large household assets
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately or highly controlling husband
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse by husband
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Husband's involvement in extramarital sex
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Worker's education up to 6 years or more
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Education more than the husband
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Young age
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Having two or more children
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of non-partner sexual violence
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: High acceptance of IPV
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle income group
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Household food insecurity
Number of subjects: 800
Study 30403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Work at a factory in the Export Processing Zone
Number of subjects: 800
Study 26672064 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 50 mg
Number of subjects: 281
Study 26672064 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg
Number of subjects: 281
Study 26672064 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg
Number of subjects: 281
Study 26672064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 26672064 — intervention group
Group type: EXPERIMENTAL
Intervention: All peficitinib doses (25, 50, 100, 150 mg)
Number of subjects: 281
Study 26672064 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 25 mg
Number of subjects: 281
Study 24704658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/f sound for 5 minutes and 33 seconds
Number of subjects: 26
Study 24704658 — intervention group
Group type: COMPARATOR
Intervention: Simple resting for 5 minutes and 33 seconds (Control)
Number of subjects: 26
Study 22198242 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 132
Study 20185226 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic levonorgestrel-ethinyl estradiol 150/30
Number of subjects: 314
Study 20185226 — intervention group
Group type: COMPARATOR
Intervention: Triphasic levonorgestrel-ethinyl estradiol 50-75-125/30-40-30
Number of subjects: 314
Study 17628451 — intervention group
Group type: EXPERIMENTAL
Intervention: LDE tablet of griseofulvin (125mg)
Number of subjects: 4
Study 17628451 — intervention group
Group type: COMPARATOR
Intervention: Immediate release conventional tablet of griseofulvin (125mg)
Number of subjects: 4
Study 16209891 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine or Citalopram
Number of subjects: 60
Study 16209891 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 60
Study 14556131 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 1 mg added to 3 mg/kg of 0.5% lidocaine (maximum 45 mL)
Number of subjects: 54
Study 14556131 — intervention group
Group type: COMPARATOR
Intervention: No additives to the IVRA solution (Control group)
Number of subjects: 54
Study 10364900 — intervention group
Group type: EXPERIMENTAL
Intervention: SASP 2000 (maximum 3000) mg daily (n = 68)
Number of subjects: 205
Study 10364900 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 7.5 (maximum 15) mg weekly (n = 69)
Number of subjects: 205
Study 10364900 — intervention group
Group type: EXPERIMENTAL
Intervention: SASP + MTX (n = 68)
Number of subjects: 205
Study 10364900 — intervention group
Group type: COMPARATOR
Intervention: SASP (n = 68)
Number of subjects: 205
Study 10364900 — intervention group
Group type: COMPARATOR
Intervention: MTX (n = 69)
Number of subjects: 205
Study 9345416 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous immunoglobulin (IVIG)
Number of subjects: 0
Study 9345416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1999791 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 31
Study 1999791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 6434223 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol infusion
Number of subjects: 26
Study 6434223 — intervention group
Group type: COMPARATOR
Intervention: Cold stimulation
Number of subjects: 26
Study 31712247 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0
Study 31712247 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 0
Study 28371942 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity self-management and coaching intervention
Number of subjects: 46
Study 28371942 — intervention group
Group type: COMPARATOR
Intervention: Social interaction intervention
Number of subjects: 46
Study 27221477 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified natural cycle (n=118)
Number of subjects: 236
Study 27221477 — intervention group
Group type: COMPARATOR
Intervention: Artificial cycle with GnRH-agonist (n=118)
Number of subjects: 236
Study 23937218 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-target RSVP streams (T1 and T2)
Number of subjects: 0
Study 23937218 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-target RSVP streams (T1, T2, and a third target)
Number of subjects: 0
Study 23937218 — intervention group
Group type: COMPARATOR
Intervention: Accurate reporting of T1 and T2
Number of subjects: 0
Study 22189672 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761® 120 mg twice daily
Number of subjects: 18
Study 22189672 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761® 240 mg once daily
Number of subjects: 18
Study 22189672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20629597 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 100 microg daily for 4 weeks
Number of subjects: 381
Study 20629597 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 381
Study 20629597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 17695691 — intervention group
Group type: EXPERIMENTAL
Intervention: PIKO-1 device
Number of subjects: 352
Study 17695691 — intervention group
Group type: COMPARATOR
Intervention: Conventional spirometer
Number of subjects: 352
Study 15855581 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 2532